University Hospital of Ludwig-Maximilians-University

VICTORIA, British Columbia--(BUSINESS WIRE)-- IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA), a biotherapeutic research and technology company, today announced the continuing success of PolyTope® TATX-03 antibody combination therapy to neutralize variants of concern of the COVID-19 causative virus, including the latest Omicron BA.5 subvariant, validated by an independent research organization in an authentic virus assay. Research was conducted by the Max von Pettenkofer Institute, part of the Medical Faculty of the Ludwig-Maximilians-University (LMU, Munich, Germany), who is world-renowned for their research and diagnostic services on SARS-CoV-2. The blinded studies examined the efficacy of IPA’s PolyTope® TATX-03 antibody combination therapy alongside in-house derived formulations of several commercially approved antibodies. Authentic isolates of virus variants tested in vitro by the LMU institute included 20E (EU1; B.1.177), Alpha (B1.1.7), Beta (B.1.351), Delta (B.1.617.2), Omicron lineages BA.1 (B.1.1.529.1), BA.1.1 (B.1.1.529.1.1), BA.2 (B.1.1.529.2), and BA.5 (B.1.1.529.5). Whereas commercially licensed products had difficulty to protect the susceptible cells against some of the listed coronavirus (sub)variants, IPA’s PolyTope® TATX-03 was able to neutralize all (sub)variants tested, including the currently dominant Omicron BA.5 subvariant, which has been described to display increased immune evasion compared to BA.1, BA.2 and pre-Omicron variants. As the spike trimer of the BA.4 Omicron variant is identical to BA.5 glycoprotein, the Company anticipates that the consistent neutralizing potency of TATX-03 hold true for this variant. IPA’s Chief Scientific Officer (CSO), Dr. Ilse Roodink, stated: “While underway to the first clinical trials of our PolyTope® in humans, this independent confirmation of the strength of our rationally designed combination therapy using authentic virus variants is very valuable for our ongoing discussion with the authorities. With the rapid evolution of Omicron and its variants, the need for a sustainable therapy to SARS-CoV-2 infection becomes increasingly evident”. She continued, “While our first-generation TATX-03 therapy has proven its resilience in vitro, we are confident about the anticipated in vivo efficacy in humans, as some components of our cocktail are able to mediate anti-viral effects through mechanisms which may enhance the already proven performance in the prior in vitro neutralization assays.”. ImmunoPrecise Antibodies Ltd. ImmunoPrecise Antibodies Ltd. is a biotherapeutic research and technology company that leverages network biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. Services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. For further information, visit . Forward Looking Information This news release contains forward-looking statements within the meaning of applicable United States securities laws and Canadian securities laws. Forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information contained in this news release include, but are not limited to, statements regarding the Company’s ability to successfully submit a clinical use application with respect to PolyTope® TATX-03, statements regarding regulatory approvals, statements regarding the potential of IPA’s PolyTope® TATX-03 to provide strong anti-viral effects against SARS-CoV-2/COVID-19 disease or any variant of the virus as either a prophylactic (preventative) or treatment (therapeutic), or to retain efficacy over time, and statements regarding the commencement date of first-in-human clinical phase trial. In respect of the forward-looking information contained herein, the Company has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the Company may not be successful in timely submission of an application for regulatory approval, developing its PolyTope® TATX-03 through the successful and timely completion of clinical trials, or may not receive all regulatory approvals to commence and then continue clinical trials of PolyTope® TATX-03, as well as those risks discussed in the Company’s Annual Information Form dated July 29, 2022 (which may be viewed on the Company’s pro ) and the Company’s Form 40-F, dated July 29, 2022 (which may be viewed on the Company’s pro ). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. Accordingly, readers should not place undue reliance on forward-looking information contained in this news release. The forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. The Company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

IRVINE, Calif., Aug. 17, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), today announced the company's PASCAL Precision transcatheter valve repair system received CE Mark for the treatment of mitral and tricuspid regurgitation (MR and TR). "Delivering the PASCAL Precision system to clinicians in Europe marks another significant step in our partnership with physicians who treat the large population of patients with mitral and tricuspid valve disease," said Bernard J. Zovighian, Edwards' corporate vice president, transcatheter mitral and tricuspid therapies. "Edwards has a long history of innovation, and the significant advancements in the PASCAL Precision system are designed to improve clinicians' ability to provide positive outcomes for patients with both MR and TR." The PASCAL Precision system is utilized in the treatment of patients with mitral or tricuspid regurgitation, through a single delivery system. The new system is designed to enable precise navigation and implant delivery. "The PASCAL Precision system provides significant advancements in operator experience with implant delivery," said Prof Jörg Hausleiter, Professor of Medicine and the Deputy Clinic Director at the Ludwig-Maximilians University in Munich, Germany. "Having successfully treated my first patient with the PASCAL Precision system, I found it easy to operate and the improved catheter response and stability gave me greater control to place the implant exactly where I needed to." The PASCAL Precision system includes PASCAL and PASCAL Ace implants, which feature independent grasping, atraumatic clasp and closure, and implant versatility including the ability to elongate and navigate complex anatomy. The PASCAL Precision system is one of multiple transcatheter repair or replacement therapies in development by Edwards that are designed to address mitral and tricuspid valve diseases. The company is committed to transforming the treatment of mitral and tricuspid patients, supported by a robust body of clinical evidence. About Edwards Lifesciences Edwards Lifesciences is the global leader of patient-focused innovations for structural heart disease and critical care monitoring. We are driven by a passion for patients, dedicated to improving and enhancing lives through partnerships with clinicians and stakeholders across the global healthcare landscape. For more information, visit Edwards.com and follow us on Facebook, Instagram, LinkedIn, Twitter and YouTube. This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though they are inherently uncertain and difficult to predict. Our forward-looking statements speak only as of the date on which they are made, and we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of the statement. Investors are cautioned not to unduly rely on such forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those expressed or implied by the forward-looking statements based on a number of factors as detailed in the company's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2021, and its Quarterly Reports on Form 10-Q for the quarters ended March 31 and June 30, 2022. These filings, along with important safety information about our products, may be found at Edwards.com. Edwards, Edwards Lifesciences, the stylized E logo, Edwards PASCAL, Edwards PASCAL Precision, PASCAL, PASCAL Ace, and PASCAL Precision are trademarks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners. Company Codes: NYSE:EW

20 years of research finds evidence of vascular-associated, naturally pluripotent stem cells in the adult body (vaPS cells) with encouraging potential for regenerative medicine HOUSTON--(BUSINESS WIRE)-- InGeneron Inc., a clinical stage regenerative medicine and cell therapy company, announced the publication of the first comprehensive analysis providing significant support for the existence of naturally pluripotent stem cells in all organs. Pluripotent stem cells have the ability to become any cell type of the adult body. The newly-released publication, entitled “Perspective: Why and How Ubiquitously Distributed, Vascular-Associated, Pluripotent Stem Cells in the Adult Body (vaPS Cells) Are the Next Generation of Medicine“, has been published in the journal Cells (Cells 10, 2303 (2021): ). The publication is based on 20 years of both basic and clinical research, performed primarily at Tulane University (New Orleans, LA, USA), MD Anderson Cancer Center-University of Texas (Houston, TX, USA), Methodist Research Center (Houston, TX, USA), Sanford Health University of South Dakota (Sioux Falls, SD, USA), and at Isar Klinikum (Munich, Germany). Tulane University reported on this new research publication on November 16, 2021: . The comprehensive publication provides strong evidence supporting the existence of a small, vascular-associated, pluripotent stem cell type (vaPS cell) that is ubiquitously distributed throughout all organs of the adult body. The publication highlights the existence of these vaPS cells and describes how these cells can be obtained in sufficient numbers from a patient’s own adipose (body fat) tissue collected by mini-liposuction, processed, and reintroduced into the patient at point of care, without need for further culturing or manipulation. In addition, the publication displays a number of case reports and clinical studies of successful treatments with these cells. The important findings of this publication highlight a new and encouraging generation of medicine with the potential to provide novel treatment options utilizing these cells for many patients for a broad range of indications. Dr. Eckhard Alt, Director of Cardiovascular Research at Tulane University and first author of the publication in Cells explains: “The vaPS cells we found provide in principle the same capabilities as embryonic stem cells and induced pluripotent stem (iPS) cells. However, instead of following the intrinsic signals that guide the development and differentiation of embryonic cells, the pluripotent differentiation of vaPS cells solely depends on external guidance by signals released from the respective microenvironment where the cells are located.” Dr. Christoph Schmitz, co-author of the paper and Head of the Department of Anatomy II at Ludwig-Maximilians University in Munich explains: “This means the vaPS cells are not limited to following the signals of the adipose tissue they are recovered from, but are able to differentiate into somatic cells of all three germ layers, under the guidance of the new tissue they are placed in.” Dr. Xiaowen Bai, senior author of the publication states, “A further advantage of regenerative cells isolated from adipose tissue is based on the fact that these cells can be obtained from and re-applied to the same patient at point of care, without the need for further manipulation or culturing,” Dr. Bai says. “In this way, stem cell therapy offers effective, fast and safe potential treatment options to physicians and patients.” Building on the insights obtained from years of research studying vaPS cells, InGeneron is currently conducting three actively enrolling FDA-approved clinical trials to evaluate its cell therapy platform for the treatment of musculoskeletal indications such as partial thickness rotator cuff tear, wrist osteoarthritis, and facet joint syndrome. Publication Details DOI: Citation: Alt EU, Schmitz C, Bai X. Perspective: Why and How Ubiquitously Distributed, Vascular-Associated, Pluripotent Stem Cells in the Adult Body (vaPS Cells) Are the Next Generation of Medicine. Cells 10, 2303 (2021). About the Transpose® RT System and Current Clinical Trials InGeneron’s Transpose® RT cell therapy platform consists of a processing unit, a set of disposables and Matrase®, a proprietary enzyme mixture. The platform allows the isolation of regenerative cells from the patients' own adipose tissue at point-of-care for same-day treatment. The cells are re-administered into the patient’s damaged tissue by injection under ultrasound or fluoroscopic guidance. The entire process takes less than 90 minutes. The Transpose® RT System is being investigated in several FDA-approved clinical trials for IDE approval and is available in the U.S. for research use only. More information on InGeneron’s actively enrolling clinical trials can be found at under the identifiers NCT03752827, NCT03513731, and NCT03503305. About InGeneron InGeneron is a clinical-stage biotechnology company developing novel, safe, and evidence-based cell therapies. We are setting new therapeutic standards by enabling minimally invasive treatments that unlock the healing potential of each patient’s own regenerative cells processed at the point of care for same-day treatment. We currently focus on helping patients impacted by orthopedic conditions and are conducting several clinical trials to validate our technology as a disease-modifying treatment in this space. With over 20 years of research and more than 100 peer reviewed publications, InGeneron is dedicated to developing therapies supported by clinical evidence and approved by the FDA.